Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

VyClo (ITCC-092) (AML)

Clinical study of the safety of the drug Vyxeos® (liposomal daunorubicin and cytarabine) in combination with clofarabine in children and young adults with relapsed/refractory acute myeloid leukemia (AML).
Who can enter
  • Children with acute myeloid leukemia (AML) in whom the disease has returned (relapsed) or responded insufficiently to treatment (refractory)
  • Age: 1 up to and including 21 years old


The goal of this study is to find out how safe the new drug Vyxeos® is, in combination with clofarabine, when given to children and young adults with relapsed/refractory acute myeloid leukemia. This study will establish a safe dosage of Clofarabine in combination with Vyxeos®.


Vyxeos® is a new drug that combines two known drugs (cytarabine and daunorubicin) together in a fixed ratio. This is enclosed in a lipid sphere (liposome), allowing the drugs to access leukemia cells more efficiently.

A study of 309 adults with AML showed that Vyxeos® significantly improved the average duration of survival. Preliminary results from this study are promising. Of the 38 children with relapsed/refractory AML who have received Vyxeos® in study settings to date, approximately 80% respond well to treatment.

In this study, clofarabine is added to treatment with Vyxeos®, with the goal of further improving the efficacy of treatment. Clofarabine is usually administered in combination with other chemotherapy.

In a study in 34 children with relapsed/refractory AML treated with a combination of clofarabine, cytarabine and liposomal daunorubicin, 68% of patients responded to treatment. The side effects were mainly infections. After treatment, 22 patients were able to proceed to stem cell transplantation.

In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Office.

Last reviewed

October 18, 2022